Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation
Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation
Study found that treatment with recombinant human growth hormone gave significantly greater benefits in stature for children with growth hormone deficiency (GHD), Turner syndrome, Prader–Willi syndrome, chronic renal insufficency, short stature homeobox-containing gene deficiency, and those who were small for gestational age, than for untreated children. However, treatment was considered to be cost-effective at a willingness to pay threshold of £20,000–30,000 per quality-adjusted life-year gained only for children with GHD, although the analysis is subject to a range of important uncertainties
growth hormone, systematic review, economic evaluation
Takeda, Andrea
55a013c5-ae02-46c2-b778-93060d250e2d
Cooper, Keith
ea064f58-d71d-404a-bcf3-49d243b8825b
Bird, A.
1044e5d8-2dff-41c2-afaa-377c2785e8e5
Baxter, L.
eeafbfe7-ae7e-421f-a6b6-c6d9df80b6ef
Gospodarevskaya, Elena
38d92bb3-d2e6-4400-a3f8-513c780fadb2
Frampton, G.K.
1976227d-3ecc-459e-bfba-ca85e61dfc0f
Welch, Karen
2603c214-aace-486f-8723-b006873248a5
Bryant, J.
508f497c-8b5a-468f-a37d-be9c26e4e49d
September 2010
Takeda, Andrea
55a013c5-ae02-46c2-b778-93060d250e2d
Cooper, Keith
ea064f58-d71d-404a-bcf3-49d243b8825b
Bird, A.
1044e5d8-2dff-41c2-afaa-377c2785e8e5
Baxter, L.
eeafbfe7-ae7e-421f-a6b6-c6d9df80b6ef
Gospodarevskaya, Elena
38d92bb3-d2e6-4400-a3f8-513c780fadb2
Frampton, G.K.
1976227d-3ecc-459e-bfba-ca85e61dfc0f
Welch, Karen
2603c214-aace-486f-8723-b006873248a5
Bryant, J.
508f497c-8b5a-468f-a37d-be9c26e4e49d
Takeda, Andrea, Cooper, Keith, Bird, A., Baxter, L., Gospodarevskaya, Elena, Frampton, G.K., Welch, Karen and Bryant, J.
(2010)
Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation.
Health Technology Assessment, 14 (42).
(doi:10.3310/hta14420).
(PMID:20849734)
Abstract
Study found that treatment with recombinant human growth hormone gave significantly greater benefits in stature for children with growth hormone deficiency (GHD), Turner syndrome, Prader–Willi syndrome, chronic renal insufficency, short stature homeobox-containing gene deficiency, and those who were small for gestational age, than for untreated children. However, treatment was considered to be cost-effective at a willingness to pay threshold of £20,000–30,000 per quality-adjusted life-year gained only for children with GHD, although the analysis is subject to a range of important uncertainties
Text
mon1442.pdf
- Version of Record
More information
Published date: September 2010
Keywords:
growth hormone, systematic review, economic evaluation
Identifiers
Local EPrints ID: 164599
URI: http://eprints.soton.ac.uk/id/eprint/164599
ISSN: 1366-5278
PURE UUID: dc308314-91b4-444f-82c0-a7e9dd57d19f
Catalogue record
Date deposited: 30 Sep 2010 10:33
Last modified: 18 Mar 2024 02:51
Export record
Altmetrics
Contributors
Author:
Andrea Takeda
Author:
A. Bird
Author:
L. Baxter
Author:
Elena Gospodarevskaya
Author:
G.K. Frampton
Author:
Karen Welch
Author:
J. Bryant
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
